(6beta,17beta)-17-乙炔基-6,17-二羟雌-4-烯-3-酮 | 51724-44-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: (6beta,17beta)-17-乙炔基-6,17-二羟雌-4-烯-3-酮
• 中文别名: 6β-羟基炔诺酮；6-Β羟基炔诺酮
• 英文名称: 19-nor-17α-pregn-4-en-20-yn-3-one-6β,17β-diol
• 英文别名: 6beta-Hydroxy Norethindrone；(6R,8R,9S,10R,13S,14S,17R)-17-ethynyl-6,17-dihydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
• CAS: 51724-44-8
• 化学式: C₂₀H₂₆O₃
• 分子量: 314.425
• InChiKey: RONQVEAZNZIVHW-BHJGDWCPSA-N

物化性质

• 熔点：
  196-198 °C
• 沸点：
  493.7±45.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (6beta,17beta)-17-乙炔基-6,17-二羟雌-4-烯-3-酮 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 生成 19-nor-17α-pregn-4-en-20-yn-3α,6β,17β-triol 、 19-nor-17α-pregn-4-en-20-yn-3β,6β,17β-triol
  参考文献：
  名称：

  Oxidation of lynestrenol by the fungusCunninghamella elegans

  摘要：

  Transformation of lynestrenol (19-nor-17 alpha-pregn-4-en-20-yn-17 beta-ol) (1) was carried out by incubation with Cunninghamella elegans to obtain 19-nor-17 alpha-pregn-4-en-20-yn-3-one-10 beta,17 beta-diol (2), 19-nor-17 alpha-pregn-4-en-20-yn-3-one-6 beta,17 beta-diol (3), and 19-nor-17 alpha-pregn-4-en-20-yn-3 beta,6 beta,17 beta-triol (4). Metabolite 4 was identified as a new compound. These metabolites were structurally characterised on the basis of spectroscopic techniques.

  DOI：

  10.1080/14786410701614507
• 作为产物：
  描述：

  利奈孕醇 在 potassium dihydrogenphosphate 、 葡萄糖 、 sodium chloride 作用下， 以 水 、 丙酮 、 甘油 为溶剂， 反应 288.0h， 以13.4 mg的产率得到10beta-羟基炔诺酮
  参考文献：
  名称：

  Oxidation of lynestrenol by the fungusCunninghamella elegans

  摘要：

  Transformation of lynestrenol (19-nor-17 alpha-pregn-4-en-20-yn-17 beta-ol) (1) was carried out by incubation with Cunninghamella elegans to obtain 19-nor-17 alpha-pregn-4-en-20-yn-3-one-10 beta,17 beta-diol (2), 19-nor-17 alpha-pregn-4-en-20-yn-3-one-6 beta,17 beta-diol (3), and 19-nor-17 alpha-pregn-4-en-20-yn-3 beta,6 beta,17 beta-triol (4). Metabolite 4 was identified as a new compound. These metabolites were structurally characterised on the basis of spectroscopic techniques.

  DOI：

  10.1080/14786410701614507

文献信息

• Medicaments based on progestins for dermal use
  申请人：DR.KADE Pharmazeutische Fabrik GmbH

  公开号：US20030109507A1

  公开（公告）日：2003-06-12

  The present invention relates to semisolid transcutaneous medicaments based on at least one oxidation-sensitive progestin or a pharmaceutically acceptable derivative thereof. The medicaments comprise ascorbic acid, an ascorbic acid derivative or a salt thereof and have excellent stability. Corresponding gels which comprise a combination of norethisterone acetate and estradiol are described in particular.

  本发明涉及基于至少一种对氧化敏感的孕激素或其药学上可接受的衍生物的半固体透皮药剂。这些药物包括抗坏血酸、抗坏血酸衍生物或其盐，具有极佳的稳定性。特别介绍了由醋酸炔诺酮和雌二醇组合而成的相应凝胶。
• Oxidation of lynestrenol by the fungus<i>Cunninghamella elegans</i>
  作者：M. Iqbal Choudhary、M. Atif、Atta-Ur-Rahman

  DOI：10.1080/14786410701614507

  日期：2010.1.10

  Transformation of lynestrenol (19-nor-17 alpha-pregn-4-en-20-yn-17 beta-ol) (1) was carried out by incubation with Cunninghamella elegans to obtain 19-nor-17 alpha-pregn-4-en-20-yn-3-one-10 beta,17 beta-diol (2), 19-nor-17 alpha-pregn-4-en-20-yn-3-one-6 beta,17 beta-diol (3), and 19-nor-17 alpha-pregn-4-en-20-yn-3 beta,6 beta,17 beta-triol (4). Metabolite 4 was identified as a new compound. These metabolites were structurally characterised on the basis of spectroscopic techniques.